Topical CP-690,550 For Chronic Plaque Psoriasis

• Status: Completed
• Trial end date: 2009-07-24
• Target enrollment: 0
• Participant gender: All

Summary

Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tofacitinib

Criteria

Inclusion Criteria:

• Having chronic plaque psoriasis for at least 6 months

• Able to withdraw all prior psoriasis treatments

• Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study

Exclusion Criteria:

• Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis

• Pregnant or lactating women

• Unwilling to use appropriate contraceptive methods